What is Diabeloop?
Founded in 2015 by Dr. Guillaume Charpentier and Erik Huneker, Diabeloop operates at the intersection of medical research and digital health innovation. The company specializes in developing automated therapeutic solutions that remove the necessity for over 100 daily decisions for patients with Type 1 diabetes. By leveraging advanced algorithms and collaborating with key research institutions like CEA-Leti, Diabeloop has established itself as a critical player in the healthtech ecosystem. Its market position is defined by its ability to integrate complex medical data into user-friendly, automated systems that significantly improve patient quality of life and clinical efficacy.
How much funding has Diabeloop raised?
Diabeloop has raised a total of $141.1M across 4 funding rounds:
Series A
$15.8M
Unspecified
$16.3M
Series B
$34M
Series C
$75M
Series A (2017): $15.8M with participation from Kreaxi, Sofimac Investment Managers, and Crédit Agricole CIB
Unspecified (2017): $16.3M, investors not publicly disclosed
Series B (2019): $34M supported by CEMAG, AGIR à dom, Odyssée Venture, and ADAG
Series C (2022): $75M featuring Innovacom, LBO France, and Terumo Corporation
Key Investors in Diabeloop
Innovacom
A veteran venture capital firm with over three decades of experience, Innovacom focuses on supporting high-potential digital startups and has a proven track record in medical imaging and industrial innovation.
LBO France
A leading multi-strategy investment fund that emphasizes ESG principles and sustainable value creation, with a specific focus on digital health and innovative mid-cap enterprises.
Kreaxi
An investment management firm specializing in equity financing for innovative tech startups, providing both capital and strategic guidance to companies during their acceleration and development phases.
What's next for Diabeloop?
Following this major strategic investment, Diabeloop is well-positioned to expand its footprint in the global digital health market. The company's roadmap likely includes scaling its automated insulin delivery systems across new territories and enhancing its algorithmic capabilities to address broader patient needs. By leveraging the expertise of its diverse investor base, Diabeloop is set to solidify its role as a leader in the digital transformation of chronic disease management, focusing on sustainable growth and the continued refinement of its medical technology suite.
See full Diabeloop company page
